A new Omicron subvariant designated BA.3.2 and nicknamed Cicada has been detected in 23 countries, including across 25 or more US states through wastewater surveillance and clinical samples, and in parts of Europe where it accounts for up to 30 percent of cases in some localised pockets. The variant was first identified in South Africa in November 2024 and has been spreading quietly across regions since then. Health authorities have classified it as a variant under monitoring, which means it is being tracked carefully but has not been elevated to the higher-concern categories of variant of interest or variant of concern.
Here is everything known so far, without the panic and without the dismissal.
What Makes Cicada Different
The most striking feature of BA.3.2 Cicada is its mutation profile. The variant carries 70 to 75 mutations on its spike protein, the part of the virus that antibodies from vaccination and prior infection primarily target. For context, the original Omicron variant that caused global waves in late 2021 carried approximately 30 spike mutations, which was itself considered extraordinary at the time and was the primary reason Omicron achieved such rapid immune escape. Delta, the dominant variant before Omicron, carried approximately 10 spike mutations.
Cicada’s 70 to 75 mutations represent a substantially higher mutation load than any previous variant that has circulated widely. This raises the theoretical possibility of immune escape, meaning the variant could partially evade immunity built up through vaccination or prior infection. However the critical point that experts are emphasising is that a high mutation count does not automatically translate into higher severity or greater danger. Mutations affect transmissibility and immune escape potential, not necessarily the virus’s ability to cause serious disease.
How Widespread Is It
Cicada currently accounts for less than 1 percent of COVID cases in the United States despite being detected in more than 25 states through wastewater monitoring and clinical sampling. Its presence in wastewater across such a wide geographic footprint before it becomes dominant in clinical case counts is consistent with the pattern of early spread that characterised previous variants before they achieved dominance.
In Europe, the picture is more uneven, with some localised areas reporting Cicada accounting for up to 30 percent of cases in specific pockets. This geographic variation suggests the variant is in the early stages of expansion and has not yet achieved the kind of consistent dominance in any major market that would indicate imminent large-scale wave dynamics.
The variant has been detected across 23 countries overall, spanning multiple continents, indicating that travel-related spread has already occurred at a scale that makes containment at borders impractical.
Symptoms and Severity — What Cases Look Like
The most reassuring element of the current Cicada data is that the majority of cases reported so far have been mild to moderate in severity. Symptoms are broadly similar to those of earlier Omicron subvariants, including sore throat, fever, and fatigue. No hospital surge has been reported in any country where the variant has been detected. No evidence of higher mortality or more severe lower respiratory disease compared to recent Omicron subvariants has emerged.
Experts emphasise that existing immunity from vaccination and prior infection, particularly the T-cell immune response which targets parts of the virus beyond the spike protein mutations, is expected to continue providing meaningful protection against severe disease even if Cicada achieves partial immune escape from antibody-based immunity. This is the same mechanism that prevented Omicron from causing the hospitalisation and death rates that Delta produced despite Omicron’s greater transmissibility.
Boosters remain key for high-risk groups including the elderly, immunocompromised individuals, and those with significant underlying health conditions, where the additional antibody response from updated vaccines provides an important additional layer of protection.
India’s Response
India is tracking BA.3.2 through INSACOG, the Indian SARS-CoV-2 Genomics Consortium, which was established to monitor COVID variants through genomic sequencing of clinical samples across the country. INSACOG’s surveillance network provides early warning of new variants establishing themselves in India’s diverse population, and health authorities are monitoring the situation as it evolves. No specific domestic surge attributable to Cicada has been reported in India at the time of writing.
The Bottom Line
Cicada is a highly mutated variant that is spreading across multiple countries and warrants careful monitoring. It is not, based on current evidence, a cause for panic. The combination of its apparent mild to moderate severity profile, the absence of hospital surges, the expected continued protection from T-cell immunity against serious disease, and its current low case share even in countries where it has been detected suggests that Cicada is a variant to watch rather than a variant to fear at this stage.
The situation is evolving. The critical indicators to monitor in the coming weeks are whether Cicada begins to achieve dominant case share in major markets, whether any signal of increased severity emerges from countries with higher current prevalence, and whether hospitalisation or mortality data from those markets shows any deviation from the pattern established by recent Omicron subvariants.
Monitor, track, and stay updated through official health authority communications. Do not panic. Do ensure high-risk individuals in your family are up to date on their COVID boosters. And watch for updates from INSACOG and the WHO as the picture develops.